Peptide Pharmacology

Menu

BPC-157 / TB4 Blend

  • Home
  • BPC-157 / TB4 Blend

Contents

What is BPC-157 / TB4 Blend?

A peptide blend combines more than one peptide together to produce additive, and sometimes synergistic, effects.

The BPC-157/TB4 blend is an investigational research blend that combines the wound healing, tissue repair, and anti-inflammatory properties of both peptides to provide a more robust overall effect.

What are BPC-157 and TB4?

BPC-157 is a peptide that influences multiple biological pathways involved in healing and tissue repair. It interacts with the body’s nitric oxide system to help regulate blood flow and inflammation, supports the formation of new blood vessels (angiogenesis), and promotes cellular migration to help cells move to injured areas and rebuild damaged structures. It has also shown potential in protecting nerves and supporting nerve regeneration in animal models.

Thymosin beta 4 (TB4) is a naturally occurring peptide found in nearly every cell in the human body, encoded by a gene on the X chromosome. Its primary role is to bind to actin, a key microfilament in the cytoskeleton, helping reorganize the cell’s structural framework and influence how cells move. Research has shown that TB4 plays an important role in tissue repair, helping cells migrate to the site of injury so they can rebuild and heal damaged tissue.

Because BPC-157 and TB4 work in different ways to produce similar results, their combination is thought to be at least additive, and potentially synergistic.

What is BPC-157/TB4 Blend Used For?

  • Investigational used for aiding in wound healing and tissue repair, especially muscles, tendons, ligaments
  • Reducing inflammation
  • Joint support: By supporting connective tissue repair, this combination may play a role in joint recovery following injury.
  • Nerve protection: Experimental models suggest potential benefits in nerve healing and protection after trauma.

Side Effects of BPC-157/TB4 Blend

Limited data shows that BPC-157 and TB4 individually are well-tolerated with minimal side effects. Most of the side effects have been due to the injection rather than the peptides. Please see the pages for BPC-157 and TB4 for more details.

BPC-157/TB4 Blend Dosing Protocol (for Research)

Investigational formulations of BPC-157 and TB4 usually contain both peptides in an equal 1:1 ratio (example, 10 mg of each). Below is a suggested protocol for research use (subcutaneous injection).

  • 1Week 1: 0.5 mg of each daily (1 mg total)
  • 2Weeks 2 and beyond: 1 mg of each daily (2 mg total)
Click here to learn how to prepare peptides for research

Recommended BPC-157/TB4 Source (for Research)

GenPeptide.com

References

Sikiric P, et al. Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal and extra-intestinal healing. Curr Pharm Des. 2011;17(16):1612–1632.

View Source

Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-5. doi: 10.2174/13816128113199990421. PMID: 23782145.

View Source

Xue B, et al. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4596-605.

View Source

Sosne G, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022 Dec 29;24(1):554.

View Source

Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021 Sep;25(17):8222-8228.

View Source